Bliss GVS Pharma Share Price
671.00+31.65 (+4.95%)
+322.92% past 1 Year
Bliss GVS Pharma Limited is a fast-growing Pharmaceutical Company with a proven track record of developing manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market.
Corporate filings & documents
Announcements
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer Advertisement in accordance with Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended for the attention of the public shareholders of Bliss GVS Pharma Ltd ("Target Company").
2 days agoSBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer Advertisement in accordance with Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended for the attention of the public shareholders of Bliss GVS Pharma Ltd ("Target Company").
2 days agoPlease find enclosed herewith the Newspaper Publication regarding the extension of the Special Window for Re-Lodgement of Transfer Request of Physical Shares.
1 week agoPlease find enclosed herewith the Newspaper Publication regarding the extension of the Special Window for Re-Lodgement of Transfer Request of Physical Shares.
1 week agoPlease find enclosed herewith the Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.
2 weeks agoPlease find enclosed herewith the Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.
2 weeks agoPlease find enclosed herewith the Postal Ballot Notice ("Notice") dated August 12 2026 alongwith the Explanatory Statement for seeking approval of Members of the Company by way of remote e-voting process to transact the business as set out in the Notice.
2 weeks agoPlease find enclosed herewith the Postal Ballot Notice ("Notice") dated August 12 2026 alongwith the Explanatory Statement for seeking approval of Members of the Company by way of remote e-voting process to transact the business as set out in the Notice.
2 weeks agoPlease find enclosed herewith the copies of newspaper advertisement published regarding the extract of statement of Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30 2026.
3 weeks agoPlease find enclosed herewith the copies of newspaper advertisement published regarding the extract of statement of Un-audited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30 2026.
3 weeks agoPlease find enclosed herewith the outcome of Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ("the Company")in its meeting held today i.e. on August 12 2026 has granted 320000 (Three Lakh Twenty Thousand) Stock Options under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019 to the eligible employees of the Company.
3 weeks agoPlease find enclosed herewith the outcome of Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ("the Company")in its meeting held today i.e. on August 12 2026 has granted 320000 (Three Lakh Twenty Thousand) Stock Options under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019 to the eligible employees of the Company.
3 weeks agoWe wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday August 12 2026 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (LODR) Regulations 2015 the Board has considered and approved the business matters as enclosed herewith.
3 weeks agoWe wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday August 12 2026 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (LODR) Regulations 2015 the Board has considered and approved the business matters as enclosed herewith.
3 weeks agoWe wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday August 12 2026 through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM") with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Board has considered and approved the following matter amongst others:1.The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026. A copy of the unaudited standalone and consolidated financial results along with the Limited Review Report of the Auditors are enclosed below.2.The draft of the Postal Ballot Notice seeking the approval of members of the Company for the appointment of Mr. Santosh Parab (DIN: 01622988) as a Director of the Company in the capacity of Non-Executive Non-Independent Director of the Company.
3 weeks agoWe wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday August 12 2026 through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM") with the deemed venue being the Registered Office of the Company. Pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Board has considered and approved the following matter amongst others:1.The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026. A copy of the unaudited standalone and consolidated financial results along with the Limited Review Report of the Auditors are enclosed below.2.The draft of the Postal Ballot Notice seeking the approval of members of the Company for the appointment of Mr. Santosh Parab (DIN: 01622988) as a Director of the Company in the capacity of Non-Executive Non-Independent Director of the Company.
3 weeks agoWe would like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. August 11 2026 has approved the allotment of 31 250 equity shares of the face value Re 1/- to the eligible employees who have exercised their stock options under the Bliss GVS Pharma Limited- Employee Stock Option Plan (Bliss GVS ESOP - 2019)
3 weeks agoWe would like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. August 11 2026 has approved the allotment of 31 250 equity shares of the face value Re 1/- to the eligible employees who have exercised their stock options under the Bliss GVS Pharma Limited- Employee Stock Option Plan (Bliss GVS ESOP - 2019)
3 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Life Insurance Corporation of India
3 weeks agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Life Insurance Corporation of India
3 weeks agoBliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday August 12 2026 at the registered office of the Company to consider and approve inter alia the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoBliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday August 12 2026 at the registered office of the Company to consider and approve inter alia the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoSBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended and Corrigendum to the Detailed Public Statement for the attention of the Public Shareholders of Bliss GVS Pharma Ltd ("Target Company").
1 month agoSBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 as amended and Corrigendum to the Detailed Public Statement for the attention of the Public Shareholders of Bliss GVS Pharma Ltd ("Target Company").
1 month agoPlease find attached detailed intimation regarding resignation of Mr. Sachin Saboo Senior Management Personnel of the Company pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
1 month agoPlease find attached detailed intimation regarding resignation of Mr. Sachin Saboo Senior Management Personnel of the Company pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
1 month agoPlease find attached copies of the newspaper publications containing recommendation of the Committee of Independent Directors.
1 month agoPlease find attached copies of the newspaper publications containing recommendation of the Committee of Independent Directors.
1 month agoPlease find enclosed herewith the Notice sent to shareholders w.r.t. the transfer of Unclaimed Final Dividend 2018-2019 and its corresponding shares to the IEPF Authority.
1 month agoPlease find enclosed herewith the Notice sent to shareholders w.r.t. the transfer of Unclaimed Final Dividend 2018-2019 and its corresponding shares to the IEPF Authority.
1 month agoPlease find attached the intimation of recommendations by the Committee of Independent Directors pursuant to Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 on Open Offer made by the Anupam Rasayan India Limited together with PAC to the Public Shareholders of the Bliss GVS Pharma Limited.
1 month agoPlease find attached the intimation of recommendations by the Committee of Independent Directors pursuant to Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 on Open Offer made by the Anupam Rasayan India Limited together with PAC to the Public Shareholders of the Bliss GVS Pharma Limited.
1 month agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Clarus Capital I & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Clarus Capital I & Others
1 month agoPlease find enclosed herewith the Newspaper publication regarding Notice to Shareholders for Transfer of Unclaimed Final Dividend 2018-2019 and its corresponding Equity Shares to IEPF.
1 month agoPlease find enclosed herewith the Newspaper publication regarding Notice to Shareholders for Transfer of Unclaimed Final Dividend 2018-2019 and its corresponding Equity Shares to IEPF.
1 month agoLetter of Offer dated July 18 2026 received from SBI Capital Markets Limited the manager to the Open Offer appointed by Anupam Rasayan India Limited along with PAC.
1 month agoLetter of Offer dated July 18 2026 received from SBI Capital Markets Limited the manager to the Open Offer appointed by Anupam Rasayan India Limited along with PAC.
1 month agoAddendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited the acquirer for the addition of PAC.
1 month agoAddendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited the acquirer for the addition of PAC.
1 month agoPlease find enclosed herewith the Voting Results alongwith the Scrutinizer Report for the 41st Annual General Meeting of the Company held on Wednesday July 15 2026.
1 month agoPlease find enclosed herewith the Voting Results alongwith the Scrutinizer Report for the 41st Annual General Meeting of the Company held on Wednesday July 15 2026.
1 month agoPlease find attached herewith the proceedings of 41st Annual General Meeting of Bliss GVS Pharma Limited.
1 month agoPlease find attached herewith the proceedings of 41st Annual General Meeting of Bliss GVS Pharma Limited.
1 month agoPlease find enclosed herewith the details of KMPs for reporting Disclosure of Material Events to Stock Exchanges.
1 month agoPlease find enclosed herewith the details of KMPs for reporting Disclosure of Material Events to Stock Exchanges.
1 month agoWe like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. July 07 2026 has approved the allotment of 1 87 750 equity shares of the face value of Re. 1/- each to the eligible employee who their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019).
1 month agoWe like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. July 07 2026 has approved the allotment of 1 87 750 equity shares of the face value of Re. 1/- each to the eligible employee who their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019).
1 month agoEnclosed herewith is the intimation regarding the Change in Management of the Company.
2 months agoEnclosed herewith is the intimation regarding the Change in Management of the Company.
2 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2026-07-08
Dividend
1.0
2026-02-18
Dividend
0.5
2025-07-24
Dividend
0.5
2024-07-18
Dividend
0.5
2023-07-12
Dividend
0.5
2022-06-20
Dividend
0.5
2021-09-13
Dividend
0.5
2020-09-17
Dividend
0.5
2019-09-12
Dividend
1.0
2018-08-14
Dividend
1.0
2017-09-18
Dividend
0.6
2016-09-06
Dividend
0.5
2015-09-08
Dividend
0.5
2015-02-24
Dividend
0.2
2014-08-13
Dividend
0.5
2013-08-01
Dividend
0.4
2013-02-25
Dividend
0.3
2012-08-02
Dividend
0.4
2011-11-24
Dividend
0.35
2011-07-14
Dividend
0.3
2010-11-25
Dividend
0.3
Company details
Registered office
102, Hyde Park Saki Vihar Road Andheri (East) Mumbai Maharashtra PIN: 400072 Tel No: 022-42160000 / 28505387 Fax No: 022-28563930 Email: [email protected] Internet: www.blissgvs.com
Registrars
C 101, 247 ParkLBS RoadVikhroli WestMumbai - 400083022-28207203-05-49186178-79022-28207207 C 101, 247 Park LBS Road Vikhroli West PIN: Tel No: 91-022-28207203-05-49186178-79 Fax No: 91-022-28207207 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Aditi Bhatt, Company Secretary & Compliance Officer
Nandkumar chodankar, Chairman
Narsimha Shibroor Kamath, Managing Director
Shilpa Bhatia, Non Executive Independent Woman Director
Vijayanarayanan Mahadevan, Non Executive Independent Director
Deepak R Shah, Non Executive Independent Director
Santosh Parab, Additional Director
Details
BSE 506197
NSE BLISSGVS
ISIN INE416D01022